Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Feasibility of DOAC Dipstick point-of-care testing in patients with acute stroke and transient ischemic attack.

Cerebrovascular diseases extra·2026

Same author

Longitudinal Non-interventional Changes of the FORTA Score are Associated with Changes of Cognitive and Physical Function Tests in Community-Dwelling Older People.

Drugs & aging·2026

Same author

Editorial: Optimizing medication management in older adults: addressing polypharmacy, deprescribing and represcribing challenges.

Frontiers in medicine·2026

Same author

Diagnostic Performance of a DOAC Urine Dipstick in Obese Outpatients with Atrial Fibrillation: Comparison with Plasma Concentrations.

Journal of clinical medicine·2026

Same author

[Why represcribing instead of deprescribing?]

Innere Medizin (Heidelberg, Germany)·2026

Same author

Evaluating the translational value of preclinical models: Available tools and frameworks, challenges and strategies.

Alternatives to laboratory animals : ATLA·2025

Search research articles

Related Experiment Video

Updated: May 31, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

New anticoagulants - promising and failed developments.

Job Harenberg¹, Svetlana Marx, Martin Krejczy

¹Clinical Pharmacology, Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim, Germany. job.harenberg@medma.uni-heidelberg.de

British Journal of Pharmacology

|July 12, 2011

Summary

New anticoagulants, including direct and indirect factor Xa (FXa) and thrombin inhibitors, are emerging as alternatives to traditional options. While some have shown promise, ongoing research and cost-effectiveness analyses are crucial for their widespread adoption.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Related Experiment Videos

Last Updated: May 31, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Area of Science:

Pharmacology and Thrombosis Research
Drug Development and Clinical Trials

Background:

Conventional anticoagulants like heparins and vitamin K antagonists have limitations.
New direct and indirect acting factor Xa (FXa) and thrombin inhibitors are under development to improve safety and efficacy.
Previous agents such as ximelagatran and idraparinux did not meet safety expectations.

Purpose of the Study:

To review the development and current status of novel oral anticoagulants.
To discuss their applications in preventing and treating thromboembolic disorders.
To assess the cost-effectiveness of these new anticoagulant therapies.

Main Methods:

Review of current literature on novel anticoagulant drugs.
Analysis of clinical trial data for efficacy and safety profiles.
Evaluation of economic data, including quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs).

Main Results:

Rivaroxaban and dabigatran are approved for specific post-operative thromboembolic prevention.
Dabigatran is also approved for embolism prevention in atrial fibrillation patients.
Multiple novel anticoagulants targeting FXa and thrombin are in various stages of investigation for diverse indications.

Conclusions:

Novel anticoagulants offer potential advantages over traditional therapies for venous and arterial thrombotic disorders.
Current cost-effectiveness is high but may improve with broader indications and market entry.
Further research and real-world data are needed to fully establish the value of these agents.